

Resource Summary Report

Generated by [RRID](#) on Aug 9, 2026

Mouse Anti-Human CD33 Monoclonal Antibody, APC Conjugated Clone AC104.3E3

RRID:AB_615078

Type: Antibody

Proper Citation

Miltenyi Biotec Cat# 130-091-731, RRID:AB_615078

Antibody Information

URL: http://antibodyregistry.org/AB_615078

Proper Citation: Miltenyi Biotec Cat# 130-091-731, RRID:AB_615078

Target Antigen: Mouse Human CD33 APC Clone AC104.3E3

Host Organism: mouse

Clonality: monoclonal

Comments: Discontinued: 2-2018; manufacturer recommendations: Mouse IgG1 Immunofluorescence; Flow Cytometry; Flow cytometry; Immunofluorescence Detection of human or non-human primate myeloid cells

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-345. (RRID:AB_2726120).

Antibody Name: Mouse Anti-Human CD33 Monoclonal Antibody, APC Conjugated Clone AC104.3E3

Description: This monoclonal targets Mouse Human CD33 APC Clone AC104.3E3

Target Organism: non-human primate, human

Antibody ID: AB_615078

Vendor: Miltenyi Biotec

Catalog Number: 130-091-731

Record Creation Time: 20250820T050211+0000

Record Last Update: 20250820T203648+0000

Ratings and Alerts

No rating or validation information has been found for Mouse Anti-Human CD33 Monoclonal Antibody, APC Conjugated Clone AC104.3E3.

Warning: Discontinued: 2021

Discontinued: 2-2018; manufacturer recommendations: Mouse IgG1 Immunofluorescence; Flow Cytometry; Flow cytometry; Immunofluorescence

Detection of human or non-human primate myeloid cells

Info: This product is discontinued and reformatted to a higher concentration for optimized use in multicolor flow cytometry panels. The replacement product cat # is 130-113-345. (RRID:AB_2726120).

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 1 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Feyaerts D, et al. (2022) Integrated plasma proteomic and single-cell immune signaling network signatures demarcate mild, moderate, and severe COVID-19. Cell reports. Medicine, 3(7), 100680.